Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
JSVCT099
Phase 2 mab completed
Quick answer
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen for COVID-19 is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- COVID-19
- Phase
- Phase 2
- Modality
- mab
- Status
- completed